Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the GroupÕs 2025 Vision to become a ÒGlobal Pharma Innovator with Competitive Advantage in Oncology,Ó Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. In Europe we are operating in 12 countries, our European headquarters is in Munich, Germany, and not far from there, one of our global production plants is located in Pfaffenhofen. For more information, please visit: www.daiichi-sankyo.eu. Imprint: https://www.daiichi-sankyo.eu/meta-navigation/imprint This channel is provided by Daiichi Sankyo Europe GmbH, the European affiliate of the pharmaceutical company Daiichi Sankyo. All information posted by Daiichi Sankyo Europe on this channel is intended for non-US, non-Canada & non-UK visitors. Daiichi Sankyo Europe is not responsible for any content posted by third parties in the comments section.